The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics of genomic alterations in circulating tumor DNA (ctDNA) in patients (Pts) with advanced gastrointestinal (GI) cancers in nationwide large-scale ctDNA screening:SCRUM-Japan Monstar-Screen.
 
Yoshiaki Nakamura
Research Funding - Genomedia (Inst); Guardant Health (Inst); Taiho Pharmaceutical (Inst)
 
Takao Fujisawa
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Naoki Takahashi
No Relationships to Disclose
 
Masahiro Goto
Honoraria - Daiichi Sankyo; Eisai; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Lilly; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kazuhiro Yoshida
Honoraria - Asahi Kasei; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Eisai; Johnson & Johnson; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Novartis; Olympus; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Sanwa Kagaku Kenkyusho; SBI Pharmaceuticals; Taiho Pharmaceutical; Takeda; Teijin Pharma; TERUMO; Tsumura & Co.; Yakult Honsha
Research Funding - Abbott (Inst); Abbvie (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Biogen (Inst); Celgene (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline K.K. (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); KCI (Inst); Koninklijke philips (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Meiji Seika Kaisha (Inst); Merck Serono (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Takeshi Kawakami
Honoraria - Bayer Yakuhin; Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Taito Esaki
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Amgen Astellas BioPharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); IQVIA (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Quintiles (Inst)
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Naohiro Nishida
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); Daiichi Sankyo; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; Merck Sharp & Dohme; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Takashi Ohta
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Teijin Pharma
 
Naomi Kuramoto
No Relationships to Disclose
 
Satoshi Horasawa
No Relationships to Disclose
 
Yasutoshi Sakamoto
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Sysmex; Takeda
 
Takayuki Yoshino
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)